Rituximab in Lymphomatoid GranulomatosisHernández-Marqués, Carmen MD; Lassaletta, Alvaro MD; Torrelo, Antonio MD; López-Pino, Miguel Ángel MD; Álvarez-Coca, Javier MD; De Prada, Inmaculada MD; Hernández-Martín, Ángela MD; Madero, Luis MDJournal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p e69–e74 doi: 10.1097/MPH.0b013e31827e63a6 Online Articles: Clinical and Laboratory Observations Abstract Author Information Background: Lymphomatoid granulomatosis (LG) is an Epstein-Barr virus–associated, multisystemic disease that combines a granulomatous inflammatory process with lymphoproliferative potential. It is a rare disorder with a variable clinical presentation ranging from an indolent process to an aggressive B-cell lymphoma. Outcome is unpredictable, and a standard treatment has not yet been established. Cases treated with rituximab, an anti-CD20 monoclonal antibody, have been reported with variable results. Observation: We report on 2 children with LG treated with rituximab and review the literature. The first patient had good response but the second did not. Conclusions: Rituximab is a treatment option for LG. Departments of *Pediatric Hematology-Oncology †Dermatology ‡Radiology §Paediatrics ∥Pathology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain The authors declare no conflict of interest. Reprints: Alvaro Lassaletta, MD, Department of Paediatric Haematology-Oncology, Hospital Infantil Universitario Niño Jesús, Avenida Menéndez Pelayo 65, Madrid 28009, Spain (e-mail: email@example.com). Received June 14, 2012 Accepted November 15, 2012 Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.